Stock listing
CSE:RVV Revive Therapeutics Ltd. Stock
Home listing (CSE) of Revive Therapeutics Ltd.
Follow Revive Therapeutics Ltd. into a list and get an email when it puts out news.
Share price · CSE:RVV
$0.01 CAD 0.00 (0.0%)
Close on Nov 20, 2026
- Day range
- $0.01 – $0.01 CADNov 20, 2026
- Volume
- 1.55M sharesNov 20, 2026
- Market cap
- $4.45M CADAt the close on Nov 20, 2026 · price × 444.6M shares outstanding
- 52-week range
- $0.0050 – $0.08 CADLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $3,708 CADMedian day 60,830 shares · 4 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| CSE:RVV · Home | $0.01 CAD | 0.00 (0.0%) | 1,548,000 | $0.01 | $0.01 | $0.01 | $0.01 | Close on Nov 20, 2026 |
| OTC:RVVTF | $0.0070 USD | -0.0001 (-1.4%) | 179,500 | $0.0076 | $0.0076 | $0.0064 | $0.0071 | Close on Nov 20, 2026 |
| Frankfurt:31R | €0.0010 EUR | -0.0010 (-50.0%) | — | €0.0110 | €0.0120 | €0.0010 | €0.0020 | Close on Nov 19, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · CSE:RVV · CAD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.01 | 0.00 | 0.0% | $0.01 | $0.01 | $0.01 | 1,548,000 | |
| $0.01 | -0.005 | -33.3% | $0.015 | $0.015 | $0.01 | 2,306,226 | |
| $0.015 | 0.00 | 0.0% | $0.015 | $0.015 | $0.015 | 36,004 | |
| $0.015 | 0.00 | 0.0% | $0.015 | $0.015 | $0.01 | 1,171,075 | |
| $0.015 | 0.00 | 0.0% | $0.015 | $0.015 | $0.015 | 0 | |
| $0.015 | -0.005 | -25.0% | $0.015 | $0.015 | $0.015 | 10,000 | |
| $0.02 | 0.00 | 0.0% | $0.02 | $0.02 | $0.02 | 50,000 | |
| $0.02 | 0.00 | 0.0% | $0.02 | $0.02 | $0.02 | 0 | |
| $0.02 | +0.005 | +33.3% | $0.02 | $0.02 | $0.02 | 5,018 | |
| $0.015 | -0.005 | -25.0% | $0.02 | $0.02 | $0.015 | 11,700 | |
| $0.02 | +0.005 | +33.3% | $0.02 | $0.02 | $0.02 | 25,000 | |
| $0.015 | -0.005 | -25.0% | $0.015 | $0.015 | $0.015 | 135,964 | |
| $0.02 | +0.005 | +33.3% | $0.02 | $0.02 | $0.02 | 2,864 | |
| $0.015 | -0.005 | -25.0% | $0.015 | $0.015 | $0.015 | 8,100 | |
| $0.02 | 0.00 | 0.0% | $0.015 | $0.02 | $0.015 | 43,871 | |
| $0.02 | +0.005 | +33.3% | $0.02 | $0.02 | $0.02 | 212,393 | |
| $0.015 | -0.005 | -25.0% | $0.025 | $0.025 | $0.015 | 61,940 | |
| $0.02 | 0.00 | 0.0% | $0.02 | $0.02 | $0.02 | 81,000 | |
| $0.02 | 0.00 | 0.0% | $0.02 | $0.02 | $0.02 | 98,000 | |
| $0.02 | 0.00 | 0.0% | $0.02 | $0.02 | $0.02 | 88,800 | |
| $0.02 | 0.00 | 0.0% | $0.02 | $0.025 | $0.02 | 355,859 | |
| $0.02 | -0.005 | -20.0% | $0.02 | $0.02 | $0.02 | 677,356 | |
| $0.025 | 0.00 | 0.0% | $0.025 | $0.025 | $0.025 | 0 | |
| $0.025 | 0.00 | 0.0% | $0.025 | $0.025 | $0.025 | 1,654 | |
| $0.025 | 0.00 | 0.0% | $0.025 | $0.025 | $0.025 | 15,000 | |
| $0.025 | -0.005 | -16.7% | $0.025 | $0.025 | $0.025 | 10,000 | |
| $0.03 | +0.005 | +20.0% | $0.03 | $0.03 | $0.03 | 3,260 | |
| $0.025 | -0.005 | -16.7% | $0.025 | $0.025 | $0.025 | 113,000 | |
| $0.03 | +0.005 | +20.0% | $0.03 | $0.03 | $0.03 | 6,664 | |
| $0.025 | -0.005 | -16.7% | $0.025 | $0.025 | $0.025 | 60,830 | |
| $0.03 | +0.005 | +20.0% | $0.03 | $0.03 | $0.03 | 204,725 | |
| $0.025 | -0.005 | -16.7% | $0.025 | $0.025 | $0.025 | 13,800 | |
| $0.03 | 0.00 | 0.0% | $0.03 | $0.03 | $0.03 | 111,515 | |
| $0.03 | +0.005 | +20.0% | $0.03 | $0.03 | $0.03 | 9,496 | |
| $0.025 | 0.00 | 0.0% | $0.025 | $0.025 | $0.02 | 38,930 | |
| $0.025 | 0.00 | 0.0% | $0.025 | $0.025 | $0.025 | 6,000 | |
| $0.025 | -0.005 | -16.7% | $0.025 | $0.025 | $0.02 | 132,000 | |
| $0.03 | +0.01 | +50.0% | $0.025 | $0.03 | $0.025 | 652,865 | |
| $0.02 | 0.00 | 0.0% | $0.02 | $0.02 | $0.02 | 104,580 | |
| $0.02 | -0.005 | -20.0% | $0.02 | $0.02 | $0.02 | 6,110 | |
| $0.025 | 0.00 | 0.0% | $0.025 | $0.025 | $0.025 | 0 | |
| $0.025 | +0.005 | +25.0% | $0.025 | $0.025 | $0.025 | 14,000 | |
| $0.02 | -0.005 | -20.0% | $0.025 | $0.025 | $0.02 | 124,358 | |
| $0.025 | +0.005 | +25.0% | $0.02 | $0.025 | $0.02 | 6,839 | |
| $0.02 | 0.00 | 0.0% | $0.02 | $0.02 | $0.02 | 195,000 | |
| $0.02 | 0.00 | 0.0% | $0.02 | $0.025 | $0.02 | 105,720 | |
| $0.02 | 0.00 | 0.0% | $0.02 | $0.02 | $0.02 | 262,176 | |
| $0.02 | +0.005 | +33.3% | $0.02 | $0.02 | $0.02 | 422,160 | |
| $0.015 | -0.01 | -40.0% | $0.025 | $0.025 | $0.015 | 1,850,378 | |
| $0.025 | 0.00 | 0.0% | $0.025 | $0.025 | $0.025 | 1,080 | |
| $0.025 | 0.00 | 0.0% | $0.025 | $0.025 | $0.025 | 198,480 | |
| $0.025 | 0.00 | 0.0% | $0.025 | $0.025 | $0.025 | 29,098 | |
| $0.025 | 0.00 | 0.0% | $0.025 | $0.025 | $0.025 | 132,100 | |
| $0.025 | -0.005 | -16.7% | $0.025 | $0.025 | $0.025 | 26,500 | |
| $0.03 | +0.005 | +20.0% | $0.03 | $0.03 | $0.03 | 6,070 | |
| $0.025 | +0.005 | +25.0% | $0.025 | $0.025 | $0.025 | 2,000 | |
| $0.02 | -0.005 | -20.0% | $0.025 | $0.025 | $0.02 | 71,900 | |
| $0.025 | 0.00 | 0.0% | $0.025 | $0.025 | $0.025 | 36,384 | |
| $0.025 | 0.00 | 0.0% | $0.025 | $0.025 | $0.025 | 31,000 | |
| $0.025 | -0.005 | -16.7% | $0.025 | $0.025 | $0.025 | 363,000 | |
| $0.03 | +0.005 | +20.0% | $0.025 | $0.03 | $0.025 | 62,739 | |
| $0.025 | 0.00 | 0.0% | $0.03 | $0.03 | $0.025 | 589,200 | |
| $0.025 | 0.00 | 0.0% | $0.025 | $0.025 | $0.025 | 267,100 | |
| $0.025 | -0.005 | -16.7% | $0.025 | $0.025 | $0.025 | 268,000 | |
| $0.03 | +0.005 | +20.0% | $0.03 | $0.03 | $0.03 | 132,000 |
- Ticker
- CSE:RVV
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- CSE
- Currency
- CAD
What changed lately
Latest news release · Sep 15, 2026
Revive Therapeutics to Expand Bucillamine IP and Orphan Drug Portfolio Across Medical Countermeasures and Rare Diseases
Latest deck · August 2026
Investor Presentation (August 2026)
Investor deck · 16 slides
Latest news
Revive Therapeutics to Expand Bucillamine IP and Orphan Drug Portfolio Across Medical Countermeasures and Rare Diseases
Sep 15, 2026
Closed $0.02 (+33.3%) on Sep 15, 2026
Revive Therapeutics Announces Proposed Shares for Debt Settlement
Aug 19, 2026
Closed $0.025 (-16.7%) on Aug 19, 2026
Revive Therapeutics Reports Grant of Options
Aug 14, 2026
Closed $0.03 (0.0%) on Aug 17, 2026
Revive Therapeutics Reports Positive Results from DRDC Bucillamine Nerve-Agent Research Study
Aug 12, 2026
Closed $0.035 (+16.7%) on Aug 12, 2026
Revive Therapeutics Announces Closing of First Tranche of Non-Brokered Private Placement
Jul 15, 2026
Closed $0.03 (0.0%) on Jul 16, 2026
Revive Therapeutics Announces Proposed Private Placement
Jun 26, 2026
Closed $0.03 (0.0%) on Jun 29, 2026
Revive Therapeutics Announces Strategic Expansion of Bucillamine Program Across Infectious Diseases, Defence and Biothreat Medical Countermeasures
May 20, 2026
Closed $0.04 (+33.3%) on May 20, 2026
Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study
Dec 15, 2025
Closed $0.015 (0.0%) on Dec 15, 2025
Revive Therapeutics Ltd. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 8 in the last 12 months · 23 in all · newest Sep 15, 2026 · oldest 2014
- Decks
- 36 decks · latest August 2026
Where Revive Therapeutics Ltd. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| CSE:RVV · Home listing · This page | CSE | Canada | CAD |
| OTC:RVVTF | OTC | United States | USD |
| gettex:31R | gettex | Germany | EUR |
| Cboe Canada:RVV | Cboe Canada | Canada | CAD |
| LS Exchange:A2AP4F | LS Exchange | Germany | EUR |
| Frankfurt:31R | Frankfurt | Germany | EUR |
| Lang & Schwarz:A2AP4F | Lang & Schwarz | Germany | EUR |
| Munich:31R | Munich | Germany | EUR |
Valuation
Statements: 4 quarters to Mar 31, 2026 · price Nov 20, 2026
- Enterprise value
- $4.50M CAD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- Negative equity
- Beta vs S&P/TSX Composite
- 0.56
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Revive Therapeutics Ltd. · CSE:RVV | US$3.10M | US$3.14M | n/a | n/a | n/a | n/a | n/a | n/a | 0.56 |
| Xenetic Biosciences, Inc. · NASDAQ:XBIO | US$3.28M | −US$2.53M | n/a | −0.8× | n/a | 0.7× | −123.7% | 0.0× | 1.46 |
| Aprea Therapeutics, Inc. · NASDAQ:APRE | US$3.25M | −US$34.60M | n/a | n/a | n/a | 0.1× | n/a | 0.0× | 0.73 |
| Spago Nanomedical AB · OMXSTO:SPAGO | US$3.21M | US$22,091 | n/a | 5.6× | n/a | 1.0× | n/a | 0.0× | n/a |
| Kiora Pharmaceuticals, Inc. · NASDAQ:KPRX | US$3.19M | −US$12.81M | n/a | −12.8× | n/a | 0.2× | n/a | 0.0× | 1.54 |
| Azitra Inc · AMEX:AZTR | US$3.13M | −US$618,677 | n/a | n/a | n/a | 0.7× | n/a | 0.0× | 0.60 |
| NuCana plc · NASDAQ:NCNA | US$3.12M | −US$21.37M | n/a | n/a | n/a | 0.1× | n/a | 0.0× | 1.58 |
| Skye Bioscience, Inc. · NASDAQ:SKYE | US$3.10M | −US$1.71M | n/a | n/a | n/a | 2.3× | n/a | 0.0× | 0.85 |
| Creative Medical Technology Holdings, Inc. · NASDAQ:CELZ | US$3.06M | −US$3.79M | n/a | −1,263× | n/a | 0.4× | n/a | 0.0× | 1.53 |
| Oncology Pharma Inc. · OTC:ONPH | US$3.04M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 1.62 |
| Imunon, Inc. · NASDAQ:IMNN | US$3.00M | US$5.90M | n/a | n/a | n/a | 1.1× | n/a | 2.6× | 0.57 |
| Median of the others | US$3.13M | −US$2.53M | −6.8× | 0.7× | −123.7% | 0.0× | 1.46 |
Team and board
Officers
| Officer | Role |
|---|---|
| Michael Frank | Chairman and Chief Executive Officer |
| Carmelo Marrelli | Chief Financial Officer |
Board
| Director | Role |
|---|---|
| Michael Frank | Chairman and Chief Executive Officer |
| Andrew Lindzon | DIRECTOR |
| Christian Scovenna | DIRECTOR |
| Joshua Herman | DIRECTOR |
| William Jackson | DIRECTOR |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2023 | May 30, 2023 · After close | −9.1% |
| Q2 2023 | Feb 27, 2023 · After close | −3.7% |
| Q1 2023 | Oct 27, 2022 · After close | +2.2% |
| Q3 2022 | May 29, 2022 · After close | +12.1% |
| Q2 2022 | Feb 28, 2022 · After close | −10.0% |
| Q1 2022 | Oct 25, 2021 · After close | +4.4% |
| Quarter to Mar 31, 2021 | May 31, 2021 · After close | −2.1% |
| Quarter to Dec 31, 2020 | Mar 1, 2021 · After close | −4.1% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (August 2026) | Investor deck | 16 slides | August 2026 |
| Investor Presentation (March 2026) | Investor deck | 13 slides | March 2026 |
| Investor Presentation (February 2026) | Investor deck | 13 slides | February 2026 |
| Investor Presentation (May 2025) | Investor deck | 15 slides | May 2025 |
| Investor Presentation (February 2025) | Investor deck | 15 slides | February 2025 |
| Investor Presentation (September 2024) | Investor deck | 15 slides | September 2024 |
| Investor Presentation (May 2024) | Investor deck | 16 slides | May 2024 |
| Investor Presentation (February 2024) | Investor deck | 16 slides | February 2024 |
| Investor Presentation (February 2024) | Investor deck | 16 slides | February 2024 |
| Investor Presentation (February 2024) | Investor deck | 16 slides | February 2024 |
All 36 decks
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Private placement of units Tranche closed: C$246,920 raised · C$0.032 a unit · 1 warrant at C$0.05 for 36 months Use of proceeds: Primarily working capital | Jul 15, 2026 | US$175,756 |
| Private placement of units Announced: up to C$1M · C$0.032 a unit · 1 warrant at C$0.05 for 36 months Use of proceeds: Working capital | Jun 26, 2026 | US$704,920 |
| Private placement of units Tranche closed: C$91,400 in the latest tranche · C$0.021 a unit · 1 warrant at C$0.05 for 36 months · free to trade Jan 19, 2026 Use of proceeds: Working capital and payment of certain trade payables | Sep 19, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in CAD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Research and development | 144.8K | 1.11M | 3.58M | 15.2M | 6.70M | 455.1K | 124.8K | 373.2K | 408.2K | |
| Selling, general and administrative | 1.40M | 2.18M | 1.94M | 2.68M | 11.9M | 3.20M | 1.19M | 1.47M | 1.26M | 873.2K |
| Operating income | -1.65M | -5.61M | -6.39M | -17.9M | -20.3M | -5.34M | -1.34M | -1.84M | -1.67M | -2.75M |
| Depreciation and amortization | 248 | 330 | 430 | 578 | 775 | 28.3K | 3.20K | 3.13K | 3.57K | 6.22K |
| EBITDA | -1.65M | -5.61M | -6.39M | -17.9M | -20.3M | -5.31M | -1.34M | -1.84M | -1.67M | -2.74M |
| Interest expense | 632 | 20.1K | 44.0K | 63.4K | 79.0K | 87.7K | 0 | 0 | 0 | 0 |
| Income before tax | -11.0M | -5.62M | -6.32M | -17.8M | -20.1M | -5.38M | -1.34M | -1.79M | -1.62M | -2.74M |
| Net income | -11.0M | -5.62M | -6.32M | -17.8M | -20.1M | -5.38M | -1.34M | -1.79M | -1.62M | -2.74M |
| Earnings per share, basic | -0.03 | -0.01 | -0.02 | -0.06 | -0.06 | -0.03 | -0.02 | -0.03 | -0.03 | -0.08 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 14.6K | 773.1K | 2.09M | 3.92M | 16.6M | 1.38M | 475.2K | 1.06M | 1.77M | 1.33M |
| Short-term investments | 0 | 100.0K | 0 | |||||||
| Receivables | 191.1K | 126.8K | 177.6K | 2.46K | ||||||
| Current assets | 68.4K | 1.14M | 2.35M | 4.16M | 16.8M | 2.16M | 528.3K | 1.09M | 1.90M | 1.35M |
| Property, plant and equipment | 1.08K | 1.40K | 1.84K | 2.42K | 3.19K | 4.23K | 5.63K | 5.66K | 7.45K | |
| Total assets | 205.0K | 10.6M | 14.3M | 17.1M | 29.8M | 8.26M | 1.28M | 1.12M | 1.92M | 1.39M |
| Accounts payable | 2.65M | 2.58M | 2.66M | 3.92M | 436.0K | 210.0K | 199.6K | 213.2K | 237.2K | |
| Current liabilities | 3.51M | 3.32M | 3.44M | 4.17M | 597.5K | 372.2K | 321.8K | 299.3K | 308.5K | 818.4K |
| Long-term debt | 66.9K | 0 | 60.0K | 60.0K | 60.0K | 40.0K | ||||
| Total debt | 327.7K | 395.8K | ||||||||
| Total liabilities | 3.66M | 3.40M | 3.60M | 4.46M | 999.7K | 831.5K | 321.8K | 299.3K | 308.5K | 818.4K |
| Shareholders' equity | -3.46M | 7.23M | 10.7M | 12.6M | 28.8M | 7.43M | 960.8K | 821.1K | 1.62M | 568.6K |
| Shares outstanding | 425.2M | 418.6M | 357.6M | 321.4M | 318.0M | 199.9M | 72.4M | 58.4M | 53.9M | 32.4M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -767.7K | -3.29M | -6.03M | -13.1M | -8.31M | -2.52M | -1.18M | -1.50M | -2.08M | -1.99M |
| Capital spending | 0 | 0 | 0 | 0 | -3.00M | 0 | -690 | -1.54K | -1.54K | -1.50K |
| Free cash flow | -767.7K | -3.29M | -6.03M | -13.1M | -11.3M | -2.52M | -1.19M | -1.51M | -2.08M | -1.99M |
| Cash from investing | 0 | -2.72M | 142.2K | -750.7K | -10.9K | -1.51K | -1.50K | |||
| Cash from financing | 39.2K | 1.98M | 4.20M | 376.4K | 26.2M | 3.28M | 1.35M | 801.2K | 2.52M | 829.2K |
| Share buybacks | 2.02M | 4.20M | 376.1K | 28.7M | 3.39M | 1.35M | 801.2K | 2.65M | 844.7K | |
| Change in cash | -758.5K | -1.31M | -1.83M | -12.7M | 15.2M | 906.2K | -585.3K | -708.2K | 435.4K | -1.16M |
Cap table
Built by 6ix from Revive Therapeutics Ltd.’s releases · as of Aug 14, 2026
- Common shares
- 444,613,939
- Fully diluted
- 472,719,870
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 444,613,939 | Jul 15, 2026 |
| Warrants | 12,605,931 | Jul 15, 2026 |
| Options and RSUs | 15,500,000 | Aug 14, 2026 |
Warrants and options
| Lot |
|---|
| Warrants · C$0.05 · expire about Jul 2029 |
| Warrants · C$0.05 · expire about Aug 2028 |
| Broker warrants · C$0.05 · expiry not stated |
| Broker warrants · C$0.05 · expiry not stated |
| Stock options · C$0.05 · expire about Aug 2031 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 444,613,939 |
| Jul 15, 2026 | 443,392,423 |
| Jun 30, 2026 | 435,676,173 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Andrew Lindzon | DIRECTOR · Since at least Nov 5, 2026 |
| Carmelo Marrelli | Chief Financial Officer · Since at least Nov 5, 2026 |
| Christian Scovenna | DIRECTOR · Since at least Nov 5, 2026 |
| Joshua Herman | DIRECTOR · Since at least Nov 5, 2026 |
| Michael Frank | Chairman and Chief Executive Officer · Since at least Sep 15, 2026 |
| William Jackson | DIRECTOR · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Revive Therapeutics Ltd.